Taken together, the evidence suggests that a varied COVID-19 disease course in CF may in part be due to the association between ACE polymorphisms, effects on ACE2 downregulation, and resulting CF features, such as pulmonary inflammation [44]. Here, ACE is linked to COVID-19.